Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Immune Design (IMDZ) Stock Price
Media coverage about Immune Design (NASDAQ:IMDZ) has been trending somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Immune Design earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 46.9443687072141 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Several equities analysts have commented on IMDZ shares. Zacks Investment Research lowered shares of Immune Design from a “buy” rating to a “hold” rating in a report on Friday, November 10th. ValuEngine lowered shares of Immune Design from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Cowen reissued a “buy” rating on shares of Immune Design in a report on Monday. Wells Fargo & Company lowered shares of Immune Design from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $29.00 to $10.00 in a report on Tuesday, October 17th. Finally, Royal Bank of Canada assumed coverage on shares of Immune Design in a report on Thursday, September 14th. They issued an “outperform” rating and a $20.00 target price on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. Immune Design has a consensus rating of “Hold” and a consensus price target of $13.19.
Immune Design (NASDAQ IMDZ) remained flat at $$3.75 on Thursday. 638,100 shares of the company traded hands, compared to its average volume of 316,735. Immune Design has a one year low of $3.50 and a one year high of $13.05.
Immune Design (NASDAQ:IMDZ) last posted its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.11. Immune Design had a negative net margin of 619.62% and a negative return on equity of 68.69%. The company had revenue of $0.52 million for the quarter, compared to the consensus estimate of $0.62 million. equities research analysts forecast that Immune Design will post -1.89 EPS for the current year.
In other Immune Design news, Director Peter Svennilson bought 2,681,000 shares of the business’s stock in a transaction that occurred on Friday, October 27th. The shares were acquired at an average cost of $4.10 per share, for a total transaction of $10,992,100.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Leo Guthart bought 2,439,000 shares of the business’s stock in a transaction that occurred on Friday, October 27th. The shares were acquired at an average price of $4.10 per share, for a total transaction of $9,999,900.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 5,300,000 shares of company stock worth $21,874,900. 20.70% of the stock is currently owned by corporate insiders.
About Immune Design
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with Analyst Ratings Network's FREE daily email newsletter.